Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

US medical groups issue vaccine guidance, urge jabs for flu, COVID and RSV

Top medical groups say current evidence shows these vaccines protect against severe illness and death.

Leading U.S. medical groups are urging individuals to receive updated flu and COVID-19 vaccinations this fall. They collaborated on September 2, 2026, to issue shot guidelines and emphasize the scientific basis behind them, aiming to reduce confusion caused by the previous administration's fluctuating advice. Flu shots are now available, and COVID-19 vaccines have also begun arriving after the FDA approved their updated versions last week.

Winter also brings the risk of RSV, another vaccine-preventable disease. While the Centers for Disease Control and Prevention (CDC) typically provides vaccination advice with assistance from its independent advisers, during the Trump presidency, some longstanding recommendations for fall virus protection and routine children's vaccinations were weakened. The CDC did not respond to inquiries about any new fall guidance.

The American Academy of Pediatrics, American Academy of Family Physicians, American College of Obstetricians and Gynecologists, and the Infectious Diseases Society of America have stepped in to fill this gap by releasing vaccination guidelines for their respective patient populations. Dr. Sandra Fryhofer, from the American Medical Association, stated that there has been significant confusion and chaos surrounding vaccine recommendations.

To address this, the medical societies are providing clear, consistent, science-based guidance on their websites, ensuring the public has access to accurate information as the federal process continues to evolve.

The medical societies agree that everyone starting at six months of age should receive flu vaccinations. However, the flu poses a greater threat to individuals aged 65 and older, pregnant women, young children, and those with chronic health issues such as asthma, diabetes, heart disease, and compromised immune systems. Both of the past flu seasons were particularly severe, resulting in unusually high numbers of child fatalities - the majority of whom were unvaccinated.

While the vaccines do not prevent all flu infections, they have been shown to prevent the most severe outcomes. According to the Vaccine Integrity Project, a public health organization at the University of Minnesota, the vaccines reduce older adults' hospitalizations due to the flu by 31%, as reported in a study published in the medical journal JAMA.

Written by urgent.news from Associated Press's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

This story

This is one outlet's version. Read the fullest account.

Read the original at aljazeera.com →

More in Health & Medicine

Would You Pay ¥55,000 To See a Doctor From Your Tokyo Hotel?

Getting sick on vacation is never ideal. Getting sick in a country where you don’t speak the language, don’t know which clinic will take you and aren’t entirely sure how to get a prescription is…

  • Tokyo-based companies launch Online Doctor for tourists
  • ¥55,000 fixed price includes medical interpretation and prescription delivery
  • Growing industry addresses challenge of navigating Japanese medical system

GC Wellbeing Partner Reports Successful Phase 3 Trial in China

A next-generation fat-dissolving drug candidate has reported positive results in a Phase 3 clinical trial in China, showing a significant reduction in submental fat after a single treatment cycle.GC…

  • Raziel Therapeutics' RZL-012 showed 30%+ higher response rate than placebo in China trial
  • Fosun Pharma and Raziel plan to file NDA with China's National Medical Products Administration
  • GC Wellbeing expects increased demand for body-contouring treatments after weight loss

Celltrion's Steqeyma Tops 16% U.S. Market Share

In the US ustekinumab market, Celltrion’s autoimmune disease treatment ‘Steqeyma’ exceeded a 16% market share in about a year since its launch.According to the pharmaceutical market research firm…

  • Celltrion's Steqeyma holds 16% U.S. market share in autoimmune disease treatment.
  • Steqeyma's market share grew by 6% in five months, from 10.2% in February to 16.2% in July.
  • Celltrion's localized sales strategy and insurance reimbursement contributed to Steqeyma's success.

More from Thursday 3 September →